PT  - JOURNAL ARTICLE
AU  - Sadoff, Jerald
AU  - Le Gars, Mathieu
AU  - Cardenas, Vicky
AU  - Shukarev, Georgi
AU  - Vaissiere, Nathalie
AU  - Heerwegh, Dirk
AU  - Truyers, Carla
AU  - de Groot, Anne Marit
AU  - Scheper, Gert
AU  - Hendriks, Jenny
AU  - Ruiz-Guiñazú, Javier
AU  - Struyf, Frank
AU  - Van Hoof, Johan
AU  - Douoguih, Macaya
AU  - Schuitemaker, Hanneke
TI  - Durability of antibody responses elicited by a single dose of Ad26.COV2.S and substantial increase following late boosting
AID  - 10.1101/2021.08.25.21262569
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.08.25.21262569
4099  - http://medrxiv.org/content/early/2021/08/26/2021.08.25.21262569.short
4100  - http://medrxiv.org/content/early/2021/08/26/2021.08.25.21262569.full
AB  - Background We evaluated the durability of SARS-CoV-2 antibody levels elicited by the single dose Janssen COVID-19 vaccine, Ad26.COV2.S, and the impact on antibody responses of boosting with Ad26.COV2.S after 6 months in clinical trial participants.Methods Spike-binding antibody and SARS-CoV-2 neutralizing antibody levels elicited by a single-dose Ad26.COV2.S (5×1010 viral particles [vp]) primary regimen and booster doses (5×1010 vp and 1.25×1010 vp) were assessed by ELISA and wild-type VNA in sera from participants in a Phase 1/2a clinical trial (Cohort 1a, 18–55 years old, N=25; Cohort 2a, 18–55 years old boosted at 6 months, N=17; Cohort 3, ≥65 years old, N=22) and a Phase 2 clinical trial (18–55 and ≥65-year old participants boosted at 6 months, total N=73). Neutralizing antibody levels were determined approximately 8 months after the primary vaccination in participants aged 18–55 years and approximately 9 months in participants aged ≥65 years. Binding antibody levels were evaluated 6 months after primary vaccination and 7- and 28-days after booster doses in both age groups.Results A single dose of Ad26.COV2.S elicited neutralizing antibodies that remained largely stable for approximately 8–9 months and binding antibodies that remained stable for at least 6 months irrespective of age group. A 5×1010 vp booster dose at 6 months post prime vaccination in 18–55-year-old adults elicited a steep and robust 9-fold increase at Day 7 post boost compared to Day 29 levels following the initial immunization. A lower booster dose of 1.25×1010 vp at 6 months in adults 18–55 and ≥65 years of age also elicited a rapid and high increase of 6–7.7 fold at Day 28 post boost compared to Day 29 levels following the initial immunization, with similar magnitude of post-boost responses in both age groups.Conclusions A single dose of Ad26.COV2.S, which demonstrated protection in a Phase 3 efficacy trial, elicited durable neutralizing and binding antibodies for at least 8 and 6 months, respectively, in adults >18 years of age at levels similar to Day 29 responses. A 5×1010 vp or 1.25×1010 vp booster dose at 6 months elicited rapid and robust increases in spike binding antibody levels. The anamnestic responses after booster immunization imply robust immune memory elicited by single-dose Ad26.COV2.S.Competing Interest StatementAll authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf and declare: all authors are employees of Janssen Pharmaceuticals, a Johnson & Johnson company.Clinical TrialNCT04436276; NCT04535453Clinical Protocols https://clinicaltrials.gov/ct2/show/NCT04436276 https://clinicaltrials.gov/ct2/show/NCT04535453 Funding StatementSupported by Janssen Vaccines & Prevention B.V. in collaboration with the Biomedical Advanced Research and Development Authority, the National Institutes of Health, the Department of Defense, and the COVID-19 Prevention Network. This project has been funded in whole or in part with Federal funds from the Office of the Assistant Secretary for Preparedness and Response, Biomedical Advanced Research and Development Authority, under Contract No. HHSO100201700018C.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All relevant ethical guidelines have been followed, all necessary IRB and/or ethics committee approvals have been obtained, all necessary patient/participant consent has been obtained and the appropriate institutional forms archived. The COV1001 study was reviewed and approved by local ethics committees (Comite d'Ethique Hospitalo-Facultaire Sain-Luc, Universite Catholique de Louvain on July 16, 2020) and institutional review boards (IRB) (approval by Advarra IRB on June 29 and July 10, 2020, for New Orleans Center for Clinical Research and Optimal Research sites, respectively). The COV2001 study was reviewed and approved by local ethics committees (Ethik-Kommission der Arztekammer Hamburg on August 19, 2020; Landesamt fur Gesundheit und Soziales Berlin Geschaftsstelle der Ethik-Kommission des Landes Berlin on August 26, 2020; Ethikkommission an der Medizinischen Fakultat der Universitat Rostock on September 01, 2020; and Raad van Bestuur UMC Utrecht on August 27, 2020) and regional ethics committees (Ethikkommission an der Medizinischen Fakultat der Universitat Rostock on September 01, 2020 and September 03, 2020; Comite Etico de Investigacion Clinica-Regional de la Comunidad de Madrid on August 28, 2020; and Central Committee on Research Involving Human Subjects (CCMO) on August 26, 2020. All participants provided written informed consent before enrollment. The trials adhere to the principles of the Declaration of Helsinki and to the Good Clinical Practice guidelines of the International Council for Harmonisation.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data sharing policy of Janssen Pharmaceutical Companies of Johnson & Johnson is available at https://www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at http://yoda.yale.edu. https://www.janssen.com/clinical-trials/transparency http://yoda.yale.edu